Hostname: page-component-5cf477f64f-r2nwp Total loading time: 0 Render date: 2025-03-31T04:48:27.310Z Has data issue: false hasContentIssue false
Accepted manuscript

Application of cognitive behavioral therapy combined with aripiprazole in the treatment of schizophrenia: a randomized controlled trial

Published online by Cambridge University Press:  27 March 2025

Jun Yan
Affiliation:
Department of Psychiatry, The Second People’s Hospital of Guizhou Province, Guiyang 550004, Guizhou, China.
Kunjie Li
Affiliation:
Department of Psychiatry, The Second People’s Hospital of Guizhou Province, Guiyang 550004, Guizhou, China.
Qiang He
Affiliation:
Department of Psychiatry, The Second People’s Hospital of Guizhou Province, Guiyang 550004, Guizhou, China.
Jie Xiong*
Affiliation:
Department of Psychiatry, The Second People’s Hospital of Guizhou Province, Guiyang 550004, Guizhou, China.
*
*Corresponding author: Dr. Jie Xiong, Department of Psychiatry, The Second People’s Hospital of Guizhou Province, No.206, South Section of Xintian Avenue, Yunyan District, Guiyang 550004, Guizhou, China. Email: [email protected], Tel: +86-0451-85553553
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

This study focused on the effect of the cognitive behavioral therapy (CBT) combined with aripiprazole on cognitive functions and psychological state of schizophrenia patients.

Method:

Seventy-eight schizophrenia patients were divided into two groups. One group received aripiprazole with conventional nursing treatment for 3 months (control group, n = 39), and the other received aripiprazole with CBT for 3 months (observation group, n = 39) (1 session per week, each session lasting 60 minutes. In the two groups before and after treatment, the severity of symptoms was evaluated using the Psychiatric Symptom Rating Scale (BPRS). Cognitive function was assessed with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). The Positive and Negative Symptom Scale (PANSS) was utilized to evaluate mental status, while the Generalized Self-Efficacy Scale (GSES) measured psychological state. Additionally, the quality of life was assessed using the General Quality of Life Inventory-74 (GQOLI-74). In the final analysis, post-treatment efficacy and complications for the two groups were counted.

Results:

Both groups showed significant improvements: BPRS and PANSS scores decreased, while RBANS, GSES, and GQOLI-74 scores increased. The observation group showed greater improvements than the control group. The total improvement rate was 89.74% (35/39) in the observation group, higher than the 71.79% (28/39) in the control group. The complication rate was 33.33% (13/39) in the observation group and 38.46% (15/39) in the control group.

Conclusion:

The treatment of CBT combined with aripiprazole for schizophrenia has a significantly positive effect on the cognitive functions and psychological state of patients.

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Scandinavian College of Neuropsychopharmacology